

Virginia Barbour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3524596/publications.pdf>

Version: 2024-02-01

47
papers

7,608
citations

361413

20
h-index

276875

41
g-index

52
all docs

52
docs citations

52
times ranked

13470
citing authors

#	ARTICLE	IF	CITATIONS
1	Openness, Integrity, Inclusion, and Innovation in Scholarly Communication: Competing or Complementary Forces?. <i>Frontiers in Research Metrics and Analytics</i> , 2021, 6, 767869.	1.9	3
2	The Hong Kong Principles for assessing researchers: Fostering research integrity. <i>PLoS Biology</i> , 2020, 18, e3000737.	5.6	200
3	The future of academic publishing: disruption, opportunity and a new ecosystem. <i>Medical Journal of Australia</i> , 2019, 211, 151.	1.7	13
4	Designing integrated research integrity training: authorship, publication, and peer review. <i>Research Integrity and Peer Review</i> , 2018, 3, .	5.2	7
5	Facilitating Prospective Registration of Diagnostic Accuracy Studies: A STARD Initiative. <i>Clinical Chemistry</i> , 2017, 63, 1331-1341.	3.2	26
6	Potential predatory and legitimate biomedical journals: can you tell the difference? A cross-sectional comparison. <i>BMC Medicine</i> , 2017, 15, 28.	5.5	266
7	Core competencies for scientific editors of biomedical journals: consensus statement. <i>BMC Medicine</i> , 2017, 15, 167.	5.5	43
8	Competing interests in journal editors. <i>BMJ: British Medical Journal</i> , 2017, 359, j4819.	2.3	1
9	An international survey and modified Delphi process revealed editors' perceptions, training needs, and ratings of competency-related statements for the development of core competencies for scientific editors of biomedical journals. <i>F1000Research</i> , 2017, 6, 1634.	1.6	20
10	A scoping review of competencies for scientific editors of biomedical journals. <i>BMC Medicine</i> , 2016, 14, 16.	5.5	31
11	Characterisation of trials where marketing purposes have been influential in study design: a descriptive study. <i>Trials</i> , 2016, 17, 31.	1.6	28
12	Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration. <i>Journal of Clinical Epidemiology</i> , 2016, 70, 68-89.	5.0	184
13	Optimal Evidence in Difficult Settings: Improving Health Interventions and Decision Making in Disasters. <i>PLoS Medicine</i> , 2014, 11, e1001632.	8.4	36
14	Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. <i>BMJ, The</i> , 2014, 348, g1687-g1687.	6.0	5,661
15	Whose Words in the Textbook?. <i>Anesthesia and Analgesia</i> , 2014, 118, 3-4.	2.2	9
16	Open letter: European Medicines Agency should remove barriers to access clinical trial data. <i>BMJ, The</i> , 2014, 348, g3768-g3768.	6.0	11
17	Restoring the integrity of the clinical trial evidence base. <i>BMJ, The</i> , 2013, 346, f3601-f3601.	6.0	26
18	Getting More Generous with the Truth: Clinical Trial Reporting in 2013 and Beyond. <i>PLoS Medicine</i> , 2013, 10, e1001379.	8.4	6

#	ARTICLE	IF	CITATIONS
19	How to Stir Up Trouble while Riding a Rollercoaster. PLoS Medicine, 2013, 10, e1001520.	8.4	4
20	The World Health Report 2012 That Wasn't. PLoS Medicine, 2012, 9, e1001317.	8.4	43
21	Let's Be Straight Up about the Alcohol Industry. PLoS Medicine, 2011, 8, e1001041.	8.4	19
22	Ten Simple Rules for Building and Maintaining a Scientific Reputation. PLoS Computational Biology, 2011, 7, e1002108.	3.2	33
23	On the Path to Global Open Access: A Few More Miles to Go. PLoS Medicine, 2011, 8, e1001014.	8.4	5
24	How ghost-writing threatens the credibility of medical knowledge and medical journals. Haematologica, 2010, 95, 1-2.	3.5	31
25	Science Must Be Responsible to Society, Not to Politics. PLoS Medicine, 2010, 7, e1000222.	8.4	3
26	The Health Crisis of Tuberculosis in Prisons Extends beyond the Prison Walls. PLoS Medicine, 2010, 7, e1000383.	8.4	23
27	Media Portrayals of Suicide. PLoS Medicine, 2009, 6, e1000051.	8.4	5
28	CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration. PLoS Medicine, 2008, 5, e20.	8.4	504
29	False Hopes, Unwarranted Fears: The Trouble with Medical News Stories. PLoS Medicine, 2008, 5, e118.	8.4	21
30	From Theory to Practice: Translating Research into Health Outcomes. PLoS Medicine, 2008, 5, e15.	8.4	7
31	The impact of open access upon public health. Bulletin of the World Health Organization, 2006, 84, 339-339.	3.3	17
32	Editors' Reply. PLoS Medicine, 2005, 2, e225.	8.4	74
33	Editors' Reply. PLoS Medicine, 2005, 2, e152.	8.4	1
34	Defective Extraembryonic Angiogenesis in Mice Lacking LBP-1a, a Member of the grainyhead Family of Transcription Factors. Molecular and Cellular Biology, 2004, 24, 7113-7129.	2.3	36
35	The story behind the science. Lancet, The, 2003, 361, 1063.	13.7	0
36	UK Biobank: a project in search of a protocol?. Lancet, The, 2003, 361, 1734-1738.	13.7	89

#	ARTICLE	IF	CITATIONS
37	Embryology revisited. Lancet, The, 2003, 362, 418.	13.7	0
38	Human stem-cell research for medicine: call for papers. Lancet, The, 2003, 362, 1778.	13.7	0
39	Mechanisms of disease. Lancet, The, 2002, 359, 2-3.	13.7	2
40	Science and myth. Lancet, The, 2002, 359, 1364.	13.7	10
41	Early online publication. Lancet, The, 2002, 359, 2216.	13.7	0
42	Asthma and the ADAMs family. Lancet, The, 2002, 360, 146.	13.7	0
43	Celebrating death—the 2002 Nobel prize in physiology or medicine. Lancet, The, 2002, 360, 1117.	13.7	5
44	How was it done?. Lancet, The, 2001, 357, 531.	13.7	0
45	Targeted Disruption of the CP2 Gene, a Member of the NTF Family of Transcription Factors. Journal of Biological Chemistry, 2001, 276, 7836-7842.	3.4	32
46	Therapeutic immunomodulation branches out. Lancet, The, 1999, 354, 1363.	13.7	0
47	Amending published articles: time to rethink retractions and corrections?. F1000Research, 0, 6, 1960.	1.6	23